Literature DB >> 9359508

Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.

J M Chessels1, G J Swansbury, B Reeves, C C Bailey, S M Richards.   

Abstract

We have analysed the prognostic influence of cytogenetic findings at diagnosis in a group of 502 children with acute lymphoblastic leukaemia (ALL), treated on MRC UKALL X, in whom clonal cytogenetic abnormalities were detected at diagnosis. Despite the overall improvement in outcome in children treated on this protocol compared with previous trials, some cytogenetically-defined groups were still associated with a poor outcome and ploidy retained some prognostic significance. Patients with high hyperdiploid ALL (39% of those with clonal abnormalities) had a favourable outcome with event free survival of 71% at 5 years. Those with near haploidy (1%), hypodiploidy (9%) and low hyperdiploidy (16.5%) had a relatively poor prognosis with event-free survival at 5 years of 17%, 42% and 49% respectively. Only two of 12 children with Ph-positive leukaemia are alive in remission and abnormalities of chromosome 11q23 were also associated with a high risk of treatment failure. In contrast, the t(1;19) was associated with improved event-free survival of 87.5% at 5 years. A number of other non-random abnormalities were identified with no clear prognostic significance. We conclude that identification of certain genetic changes remains important in the management of acute lymphoblastic leukaemia, although whether molecular diagnosis of clinically relevant abnormalities can now supplant cytogenetics in the clinical trials context remains to be determined.

Entities:  

Mesh:

Year:  1997        PMID: 9359508     DOI: 10.1046/j.1365-2141.1997.3493163.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Evidence based medicine.

Authors:  T Eden
Journal:  Arch Dis Child       Date:  2000-04       Impact factor: 3.791

Review 2.  Therapeutic trials in childhood ALL: what's their future?

Authors:  O B Eden
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

Review 3.  Chemotherapy of childhood lymphoblastic leukaemia: the first 50 years.

Authors:  J Lilleyman
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

4.  Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups.

Authors:  Sara Dyer; Emma Prebble; Val Davison; Paul Davies; Pramila Ramani; David Ellison; Richard Grundy
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 5.  Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia.

Authors:  Stephanie McGregor; Jennifer McNeer; Sandeep Gurbuxani
Journal:  Semin Diagn Pathol       Date:  2012-02       Impact factor: 3.464

6.  Ten-year experiences on initial genetic examination in childhood acute lymphoblastic leukaemia in Hungary (1993-2002). Technical approaches and clinical implementation.

Authors:  Eva Olah; Erzsebet Balogh; Laszlo Pajor; Zsuzsanna Jakab
Journal:  Pathol Oncol Res       Date:  2010-06-24       Impact factor: 3.201

7.  Cytogenetic analysis in childhood acute lymphoblastic leukemia: experience at a single institution in Korea.

Authors:  Young Joo Kwon; Jae Wook Lee; Myung Shin Kim; Pil Sang Jang; Nak Gyun Chung; Dae Chul Jeong; Yong Goo Kim; Kyung Ja Han; Soon Ju Lee; Bin Cho; Hack Ki Kim
Journal:  Int J Hematol       Date:  2008-12-25       Impact factor: 2.490

8.  Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.

Authors:  James B Nachman; Nyla A Heerema; Harland Sather; Bruce Camitta; Erik Forestier; Christine J Harrison; Nicole Dastugue; Martin Schrappe; Ching-Hon Pui; Giuseppe Basso; Lewis B Silverman; Gritta E Janka-Schaub
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

9.  Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.

Authors:  Sabina Chiaretti; Antonella Vitale; Gianni Cazzaniga; Sonia Maria Orlando; Daniela Silvestri; Paola Fazi; Maria Grazia Valsecchi; Loredana Elia; Anna Maria Testi; Francesca Mancini; Valentino Conter; Geertruy te Kronnie; Felicetto Ferrara; Francesco Di Raimondo; Alessandra Tedeschi; Giuseppe Fioritoni; Francesco Fabbiano; Giovanna Meloni; Giorgina Specchia; Giovanni Pizzolo; Franco Mandelli; Anna Guarini; Giuseppe Basso; Andrea Biondi; Robin Foà
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

10.  Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001.

Authors:  C Mitchell; S Richards; C J Harrison; T Eden
Journal:  Leukemia       Date:  2009-12-10       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.